12:00 AM
 | 
May 12, 2008
 |  BioCentury  |  Finance

EPS Watch

EPS Watch

Company 1Q08 EPS est 1Q08 EPS actual Outcome Growth from 1Q07 5/9 cls Wk chg % chg Mcap chg 5/9 Mcap
Celgene (NASDAQ:CELG) $0.34 $0.36 Beat by $0.02 125% $62.49 -$1.87 -3% -$770.9 $25,762.3
First quarter non-GAAP revenue increased 57% to $461M, with sales of Revlimid lenalidomide for multiple myeloma (MM) and myelodysplastic syndromes (MDS) rising 96% to $286.8M. Celgene also reported $113.9M in sales of Thalomid thalidomide compared with $106M...

Read the full 565 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >